Biogen CEO to step down as the drugmaker plans further Aduhelm cost cuts

Biogen's Chief Executive Officer Michel Vounatsos is stepping down as it is grappling with Medicare restricting coverage for its Alzheimer's drug Aduhelm.



Source link